Precipio Signs Additional Major HemeScreen™ Customer
NEW HAVEN, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announced a 4-year agreement with a new customer to bring HemeScreen™ technology into their lab.
Related news for (PRPO)
- Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
- Precipio Announces Q1-2025 Shareholder Update Call
- Precipio Announces Q4 and year-end 2024 Shareholder Update Call
- Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
- Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs